Noxxon CEO discusses partners and cancer combinations - Aram Mangasarian , CEO, NOXXON Pharma 00:00:00
Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications.